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There is an urgent need for improved therapies for children with high-risk neuroblastoma 
where survival rates remain low. MYCN amplification is the most common genomic change 
associated with aggressive neuroblastoma and drugs targeting PI3K/AKT/mTOR, to activate 
MYCN oncoprotein degradation, are entering clinical evaluation. Our aim was to develop and 
validate pharmacodynamic (PD) biomarkers to evaluate both proof of mechanism and proof 
of concept for drugs that block PI3K/AKT/mTOR pathway activity in children with 
neuroblastoma. We have addressed the issue of limited access to tumor biopsies for 
quantitative detection of protein biomarkers by optimizing a three-color fluorescence 
activated cell sorting (FACS) method to purify CD45-/GD2+/CD56+ neuroblastoma cells 
from bone marrow. We then developed a novel quantitative measurement of MYCN protein 
in these isolated neuroblastoma cells, providing the potential to demonstrate proof of 
concept for drugs that inhibit PI3K/AKT/mTOR signaling in this disease. In addition we have 
established quantitative detection of three biomarkers for AKT pathway activity 
(phosphorylated and total AKT, GSK3β and P70S6K) in surrogate platelet-rich plasma 
(PRP) from pediatric patients. Together our new approach to neuroblastoma cell isolation for 
protein detection and suite of PD assays provides for the first time the opportunity for robust, 
quantitative measurement of protein-based PD biomarkers in this pediatric patient 
population. These will be ideal tools to support clinical evaluation of PI3K/AKT/mTOR 
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Neuroblastoma, a malignancy originating in the sympathetic nervous system, is the most 
frequent extra-cranial solid tumor in children. Despite intensification of multimodality 
treatment, the outcome for children with high-risk disease (metastatic or MYCN amplified) 
remains poor. Sixty per cent of neuroblastoma patients experience relapse, and survival 
after relapse is only 8% (London et al., 2011). There is an urgent need to develop new drugs 
which can be fast-tracked into frontline therapy to improve cure rates for patients with high-
risk disease and to decrease toxicity in long-term survivors (Barone et al., 2013). 
 
Amplification of MYCN  is one of few genetic abnormalities in neuroblastoma affecting 20% 
of patients and is more common in high-risk cases (Brodeur et al., 1984). MYCN 
amplification is the strongest genetic alteration linked to poor prognosis in neuroblastoma 
(Seeger et al., 1985) and promotes metastatic behavior (Benard, 1995). Metastasis is seen 
in the majority (70%) of patients with high-risk neuroblastoma at the time of diagnosis (Maris 
et al., 2007) with the most common sites being bone marrow, bone and lymph nodes 
(DuBois et al., 1999). Mounting evidence for the role of MYCN in driving neuroblastoma 
(Huang and Weiss, 2013) has led to several therapeutic strategies to target this oncoprotein, 
(reviewed in (Barone et al., 2013)). Direct pharmacological inhibition of MYCN function 
through blockade of MYCN/MAX interactions (Zirath et al., 2013) is challenging and alternate 
strategies have included drugs which indirectly modulate MYCN e.g. BET bromodomain 
inhibitors that block MYCN transcription (Puissant et al., 2013) and inhibiting pathways that 
regulate stabilization of MYCN protein (Gustafson and Weiss, 2010). MYCN stability is tightly 
regulated by phosphorylation on residues T58/S62 which block its proteasomal degradation 
(Vervoorts et al., 2006). The PI3K/AKT/mTOR pathway directly regulates phosphorylation of 
MYCN, maintaining expression of active MYCN protein, and several inhibitors of this 
pathway have been shown to cause degradation of MYCN protein (Chesler et al., 2006; 




The PI3K/AKT/mTOR pathway is a high priority target in pediatric cancer for several 
reasons. On the basis of extensive pre-clinical evidence, inhibition of this pathway is 
predicted to be clinically efficacious in: i) MYCN-driven tumors, including neuroblastoma, 
medulloblastoma and rhabdomyosarcoma with aberrant amplification, expression or 
stabilization of MYCN oncoprotein, ii) tumors with aberrant activation of the PI3K/AKT/mTOR 
pathway (Opel et al., 2007) and, iii) tumors with intrinsic PI3K pathway activating mutations 
(PI3KCA, AKT) or deletions (PTEN), although these generally occur less frequently in 
pediatric than in adult cancers (Dam et al., 2006; Izycka-Swieszewska et al., 2010; Moritake 
et al., 2001). In neuroblastoma and medulloblastoma, pharmacologic inhibition of the 
PI3K/AKT/mTOR pathway in genetically engineered murine models has shown antitumor 
effects mediated by destabilization of MYCN oncoprotein (Chanthery et al., 2012; Pei et al., 
2012). Inhibitors of PI3K, PI3K/TORC, TORC and AKT are being evaluated in adult cancers 
(Porta et al., 2014) and are entering pediatric development in early phase clinical trials 
(Fouladi et al., 2014; Geoerger et al., 2012; Gore et al., 2013). In support of these trials, it 
will be crucial to incorporate pharmacodynamic (PD) biomarkers for inhibition of the 
PI3K/AKT/mTOR pathway and its target MYCN if we are to effectively prioritize use of these 
drugs.  
 
One of the key issues, particularly in the development of pediatric biomarkers is to establish 
assays suitable for use in surrogate tissues (commonly blood) and/or methods to isolate 
disseminated tumor cells, given that biopsy of primary tumor tissue is uncommon (Ang et al., 
2012). This study addresses these needs by building i) methodology to efficiently purify 
neuroblastoma tumor cells from bone marrow for protein biomarker studies, ii) a quantitative 
immunoassay to measure MYCN oncoprotein levels in neuroblastoma tumor cells, and iii) a 
set of quantitative PD biomarker assays that robustly measure PI3K/AKT/mTOR pathway 
activity in platelet-rich plasma. We demonstrate extensive pre-clinical evaluation of these 
assays and methods and pilot studies establishing assay performance in samples from 
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pediatric patients. This suite of assays can now be implemented on forthcoming clinical trials 





2. Material and methods 
 
2.1 Cell culture and drug treatment 
SHEP neuroblastoma cell lines were obtained under consent of the Bishop Laboratory, 
University of California at San Francisco Cell Culture Facility, and Kelly, BE2C, IMR32 and 
SKNAS from the American Type Culture Collection. SHEP+ cells (expressing murine MYCN) 
were previously reported by us (Chesler et al., 2006). Cell lines had either high MYCN 
expression (MYCN amplified: Kelly, BE2C and IMR32) or no expression of human MYCN 
protein (SHEP, SHEP+ and SKNAS).  Kelly and IMR32 cells were cultured in RPMI media 
with 10% FCS (PAA Laboratories) and 2mM glutamine (Gibco). All other cell lines were 
grown in DMEM containing 10% FCS and 2mM glutamine. Cell lines were maintained under 
a humidified atmosphere at 37°C with 5% CO2 and cultured for less than 6 months before 
renewal from early passage frozen stocks. All cell lines were shown to be Mycoplasma-free 
using a PCR-based assay (Minerva Biolabs) and were SNP genotyped yearly. AZD8055 
was purchased from Selleckchem. Cells were treated at the indicated concentrations or with 
an equivalent volume of DMSO for 3 h before harvesting. 
 
2.2 Patient samples 
For isolation of pediatric PRP, blood samples were collected from 24 children with solid 
tumors aged 1-18 years receiving treatment at Royal Marsden NHS Foundation Trust at a 
single time point. The 24 adult patient blood samples for PRP isolation were taken at the 
time of enrolment to Phase I trials (baseline). For isolation of neuroblastoma cells, bone 
marrow samples were collected in heparinized tubes from 14 pediatric patients treated for 
neuroblastoma. The study was conducted under Institutional Review Board approval (Royal 
Marsden Committee for Clinical Research [CCR] numbers 3083 and 3358 for adult and 
pediatric patients, respectively). For development of the FACS assay, healthy volunteer 
blood was collected with CCR approval (CCR3073). All participants/legal guardians provided 




2.3 Immunomagnetic separation 
Samples were incubated for 20 min with CD45 or CD56 MicroBeads (Miltenyi Biotec) in 
MACS buffer (Miltenyi Biotec). Immunomagnetic separation of the negative fraction (for 
CD45 depletion) or the positive fraction (for CD56 selection) was performed in MS columns 
(Miltenyi Biotec) following the manufacturer’s instructions. Pre- and Post- enriched samples 
were analysed by flow cytometry to calculate the proportion of neuroblastoma cells out of the 
total nucleated cells (purity) using APC-H7-CD45, PE-GD2 and FITC-CD56 antibodies (BD 
Bioscience) and BD LSRII flow cytometer (Becton and Dickinson). 
 
2.4 A three-color FACS assay for isolation of neuroblastoma cells from bone marrow 
For initial development of this assay, Kelly neuroblastoma cells were spiked into (adult) 
healthy volunteer blood at two concentrations: high (1.5 x 106 cells) or low (3 x 105 cells) in 
6ml whole blood. For patient bone marrow samples, 3-8 ml of bone marrow aspirate was 
collected. Samples were diluted 1:3 in ice-cold Wash buffer (MACS buffer (Miltenyi Biotec), 
5% BSA and protease and phosphatase inhibitors) and the mononuclear cell fraction 
isolated after layering onto Lymphoprep™ and centrifugation at 800 xg for 25 min. The cells 
were filtered and washed once and kept chilled. One fraction of the sample was immediately 
resuspended in Cell Lysis Buffer and frozen at -80ºC whilst the remaining fraction was 
prepared for fluorescence activated cell sorting (FACS). Samples were incubated for 20 min 
with APC-H7-CD45, PE-GD2 and FITC-CD56 antibodies (BD Bioscience), washed once and 
resuspended in 1ml Wash buffer. The cells were analyzed with BD FACSAria cell sorter 
(Beckton and Dickinson, USA) using FACSDiva software. If CD45-/GD2+/CD56+ cells were 
identified they were sorted by FACS, along with white blood cells (CD45+/GD2-/CD56-) to 
be used as a negative control. The sorted cells were pelleted, resuspended in Cell Lysis 





2.5 Western blotting 
Cells were harvested by scraping, washed once in Phosphate-buffered saline (PBS), then 
resuspended in Cell Lysis Buffer (Cell Signaling Technology) and incubated for 45 min at 
4˚C. The lysed cells were centrifuged at 16,000 xg for 15 min and the supernatant collected. 
Quantification of protein was performed using BCA protein assay (Thermo Scientific) by 
comparison with BSA standards. Equal amounts of protein (25µg) were separated by SDS-
PAGE using 4-12% Bis-Tris NuPAGE gels (Life Technologies), and transferred onto 
nitrocellulose membranes. Immunoblotting was performed with the following antibodies: 
MYCN (Santa Cruz); phospho-AKT (S473) and total AKT (Cell Signaling Technology) and 
GAPDH (Millipore) using blocking buffer (1X Tris-buffered saline, 1% Tween 20, 5% milk). 
Blots were exposed to film following incubation with SuperSignal West Pico 
Chemiluminescent Substrate (Thermo Scientific). Western blots shown are representative of 
three independent repeats.   
 
2.6 MYCN immunoassay 
Immulon2HB 96-well plates were coated with mouse MYCN antibody (Abnova) overnight at 
4°C. Wells were washed three times with 0.1% Tween 20 wash buffer and blocked for 1 h 
with blocking buffer (PBS, 1% milk). Cell lysates were added using equal quantities of 
protein in 50µl volume per well. Recombinant MYCN protein (Abnova) standards and control 
Kelly cell lysates were included on each plate for QC.  After 2 h incubation at 37°C, wells 
were washed and rabbit MYCN antibody (Novus Biologicals) added for 1.5 h. Following 3 
washes, EU-N1 anti-rabbit antibody (Perkin Elmer) was added (1:1500 in DELFIA Assay 
Buffer, Perkin Elmer) for 1 h. Three further washes were performed followed by 5 min 
incubation with DELFIA Enhancement Buffer (Perkin Elmer). Plates were read at 615nm on 
an Envision 2103 plate reader (Perkin Elmer).   
 
2.7 Measurement of PI3K/AKT/mTOR pathway signals 
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This methodology has been reported before for analysis of PI3K/AKT/mTOR pathway 
signals in PRP from adult clinical studies in our laboratory (Arkenau et al., 2014; Banerji et 
al., 2013; Kumar et al., 2014; Omlin et al., 2012; Yap et al., 2011). In brief, blood samples 
were collected in 2x 2.7ml BD Vacutainer® tubes with sodium citrate. Plasma was collected 
after centrifugation for 15 min at 200 xg, 4°C. PhosSTOP (Roche) and Cell Lysis Buffer (Cell 
Signaling Technology) were added and samples were snap frozen at −80°C. Samples were 
analyzed for total and phospho-Ser473 AKT, total and phospho-Ser9 GSK3 and total and 
phospho-Thr421/424 P70S6K using electrochemiluminescence (ECL) immunoassays (Meso 
Scale Discovery®) in 96-well plate format. For each assay pSer473 AKT and total AKT 
concentrations were back-calculated from a standard curve of recombinant AKT protein. The 
accuracy and precision of the assays were monitored using quality control (QC) samples 
created by spiking three known quantities of recombinant AKT into 10% human plasma. 
Data analysis was performed using the Meso Scale Discovery Workbench software package 












3.1 A three-color FACS method to isolate neuroblastoma cells for protein detection 
An important step early on in clinical development of a drug is to demonstrate proof of 
concept. For PI3K/AKT/mTOR inhibitors, detection of MYCN protein loss will validate this 
concept. As MYCN is not expressed in surrogate tissues, only tumor cells can be used to 
demonstrate proof of concept. Given the logistical and ethical challenges of repeat tumor 
biopsies in the pediatric population, and the high occurance of bone marrow metastasis in 
high-risk neuroblastoma (DuBois et al., 1999; Ladenstein et al., 2010), our first aim was to 
develop a methodology to enrich neuroblastoma cells from bone marrow aspirates in a form 
suitable for detection of MYCN protein. Based on the knowledge that neuroblastoma cells 
are CD45-/GD2+/CD56+ (Swerts et al., 2004), we investigated strategies including positive 
selection of CD56+ cells or depletion of CD45+ cells from the peripheral blood mononuclear 
cell (PBMC) fraction of blood using immunomagnetic beads, and fluorescence activated cell 
sorting (FACS) of CD45-/GD2+/CD56+ cells. To directly compare and optimize these 
methods we used Kelly cells spiked into adult healthy volunteer whole blood. As shown in 
Table 1, depletion of CD45 or CD56 positive selection using immunomagnetic columns 
enriched the purity of neuroblastoma cells by 1.7-fold and 3.9-fold respectively, whereas the 
FACS-based method reproducibly achieved superior enrichment (5.4-fold). We therefore 
performed further validation of the triple antibody (CD45APC-H7, GD2PE, CD56FITC) FACS 
protocol as our preferred methodology. 
 
Kelly cells were spiked into healthy volunteer blood at two different concentrations: high (1.5 
x 106 cells per 6 ml blood) and low (3 x 105 cells per 6 ml blood) and compared to pure Kelly 
cells or PBMCs from unspiked blood. Neuroblastoma cells were isolated from both high and 
low spiked samples with similar efficiency using the FACS-based method (Fig. 1A). 
Enrichment was 71% and 74% for high and low spiked samples, respectively compared with 
77% for Kelly cells alone (Fig. 1B) and the percentage of neuroblastoma cells recovered  (in 
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relation to the number of cells spiked) was approximately 30% in all samples (Fig. 1C). The 
fold enrichment of Kelly cells post-sorting was statistically significant with an average of 8.1-
fold for high spiked samples and 33.0-fold for low spiked samples compared to the pre-
sorted samples (p<0.001 and p=0.003, respectively). Together these data suggest that this 
three-color FACS method can be used to reproducibly isolate neuroblastoma cell line cells 
with high purity from blood regardless of the initial percentage of cells spiked into the 
sample.  
 
3.2 Isolation of neuroblastoma cells from patient bone marrow 
Having determined that three-color FACS can isolate neuroblastoma cell line cells from 
spiked healthy volunteer blood, the next step was to confirm that the FACS protocol could be 
effectively applied to extract tumor cells from bone marrow aspirates. Therefore, a pilot study 
was set up to collect and process bone marrow samples from patients diagnosed with 
neuroblastoma (n=14). Firstly, we confirmed that we could detect the presence of CD45-
/GD2+/CD56+ cells in 11 bone marrow aspirates analyzed from 7 of the 14 patients (see 
Table 2). Bone marrow involvement was confirmed independently from bone marrow smears 
and trephine biopsies, by morphology and immunocytochemistry, for all of the positive 
samples except those with a very low percentage of CD45-/GD2+/CD56+ cells (Table 2), 
likely due to multicolor flow cytometry analysis being much more sensitive than routine 
techniques to detect bone marrow infiltration (Beiske et al., 2005). Importantly, all the 
samples which we found to be negative for CD45-/GD2+/CD56+ cells also had no detectable 
neuroblastoma cells by independent clinical laboratory analysis (data not shown) and all 
samples with >1% tumor cells by flow cytometry were confirmed to have heavy infiltration. 
Therefore, we were confident that our isolation methodology specifically identifies 
neuroblastoma cells present in samples.  
 
In bone marrow aspirates with a detectable level of infiltrating neuroblastoma cells we used 
our three-color FACS methodology to isolate the neuroblasts for PD biomarker analysis (Fig. 
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2A). The extent of bone marrow involvement was variable between samples with range 0.01 
- 15.1% and mean of 3.6% (Fig. 2B). Regardless of the extent of bone marrow infiltration, 
FACS sorting to enrich for neuroblastoma cells resulted in a similar final purity with a mean 
of 69.2%±10.6 from six isolated samples from which sufficient cells were collected for 
additional flow cytometry analysis (Fig. 2B). Therefore, a greater enrichment was achieved in 
samples with lower levels of tumor cell infiltration (Table 2). The purity of the remaining five 
isolated samples was not determined due to insufficient cell numbers (≤10,000 cells per 
sample). Overall, these results verified that FACS is an efficient methodology for enrichment 
of tumor cells from the bone marrow of neuroblastoma patients. 
 
3.3 A novel immunoassay to detect MYCN protein 
We next sought to develop a methodology to accurately and quantitatively measure levels of 
total MYCN protein in neuroblastoma cells. We used DELFIA®, a well proven robust and 
sensitive technology to develop a novel in-house immunoassay to measure MYCN protein. 
We standardized our assay using recombinant MYCN protein, showing a strong linear 
correlation between protein concentration and europium counts (Fig. 3A). The assay was 
superior to immunoblotting in sensitivity for detection of MYCN protein with signals above 
background using ≥0.2µg total protein from Kelly cell lysate (Supplementary Fig. S1).   
 
The specificity for detection of MYCN protein in cell lysates was assessed by evaluating 6 
neuroblastoma cell lines.  Cell lysates from all MYCN-amplified cell lines (BE2C, IMR32 and 
Kelly) showed high signals in the immunoassay using either 25μg or 10μg total protein, 
which correlated well with MYCN levels determined by western blotting (Fig. 3B and C). In 
SHEP+, SHEP and SKNAS cells (lacking human MYCN) signals were equivalent to 
background (Fig. 3B and C).   
 
Inhibition of PI3K/AKT/mTOR signaling stimulates degradation of MYCN through altered 
MYCN phosphorylation (Chesler et al., 2006; Johnsen et al., 2008). In Kelly neuroblastoma 
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cells, MYCN protein was depleted following treatment with the TORC inhibitor AZD8055 in a 
dose-dependent manner (Fig 3D). Our in-house immunoassay accurately quantified this 
decrease in MYCN protein expression (Fig. 3E). Taken together, these data provide good 
pre-clinical validation of the MYCN immunoassay for detection of MYCN protein in 
neuroblastoma cells prior to and post treatment with inhibitors that target the 
PI3K/AKT/mTOR pathway.       
 
3.4 Preservation of MYCN protein in FACS isolated neuroblastoma cells 
Since a key objective of this study was to be able to measure MYCN protein in 
neuroblastoma cells isolated from patients, we  first needed to confirm whether the levels of 
the MYCN oncoprotein were preserved throughout the isolation procedure using cultured 
neuroblastoma cells spiked into healthy volunteer blood. Importantly, Kelly cells that were 
processed and isolated by FACS immediately after spiking into blood showed similar MYCN 
signals to Kelly cells alone (Fig. 4A). Performing the processing at 4ºC at all stages 
preserved protein signals better than processing at room temperature, which resulted in 
39.1±6.5% lower signals post-sorting. We also investigated MYCN protein levels in spiked 
samples that were not processed straightaway (as may happen in a clinical trial situation) 
and instead stored at 4ºC for 1, 4 or 24 hours. MYCN signals were slightly reduced over time 
with a significant decrease post-sorting of 35.3% at 24 hours compared with Kelly cells alone 
that were processed immediately (Fig. 4A), even though the efficiency in isolating Kelly cells 
remained consistent in samples that were stored on ice before processing (Supplementary 
fig. 2). These findings indicate that samples should be processed in less than 24 hours and 
ideally starting within 4 hours of collection.  
 
We next assessed the stability of stored lysates using Kelly cells that were spiked into 
healthy volunteer blood and isolated by 3-color FACS sorting. The isolated cells were lysed, 
aliquoted and snap frozen, then either kept on dry ice overnight to simulate sample 
transportation conditions before being stored at -80ºC, or stored at -80ºC directly.  Samples 
15 
 
were thawed for MYCN analysis after different periods of storage.  MYCN signals were 
found to be maintained after 1 week and 4 weeks of storage and were unaffected by 
temporary storage on dry ice (Fig. 4B).  
 
Based on our stability data we recommend that in order to preserve MYCN protein signals in 
isolated neuroblastoma cells in multi-site clinical trial setting, bone marrow aspirates should 
be processed promptly on site to isolate neuroblastoma cells and frozen lysates shipped to a 
single laboratory site for PD biomarker analysis within one month (Fig. 4C) 
 
3.5 Quantitative measurement of MYCN protein in isolated neuroblastoma cells 
We next analyzed MYCN levels in Kelly cells that were spiked into healthy volunteer blood at 
high and low concentrations. Consistent with the enrichment of neuroblastoma cells 
(expressing MYCN) in the high and low spiked samples (Fig. 1B), signals for MYCN were 
increased post-sorting compared with pre-sorted samples (Fig. 4D) showing that the 
isolation method can effectively be used in combination with MYCN protein measurement in 
samples with varying numbers of tumor cells. 
 
To further corroborate whether quantification of MYCN protein levels as a pharmacodynamic 
biomarker is feasible in isolated neuroblastoma cells, Kelly cells were pre-treated with 
AZD8055 before spiking into healthy volunteer blood and then sorted by FACS. Using equal 
amounts of total protein in spiked samples and the isolated neuroblastoma cells, samples 
were analyzed using the MYCN immunoassay. MYCN expression was decreased by 
AZD8055 in a dose-dependent manner in Kelly cells spiked into blood and importantly, the 
drug-mediated reduction in MYCN protein was still measurable in the Kelly cells that had 
been isolated from whole blood (Fig. 4E).   
 
To monitor intra-assay reproducibility and inter-assay reliability, a standard curve was 
generated using MYCN recombinant protein and quality controls (QCs) were prepared from 
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Kelly cell lysates and included in each assay. Levels of intra- and inter- assay variation, 
assessed by coefficient of variation (%CV), were acceptable for each point of the standard 
curve and the interpolated QCs (Supplementary Fig. S3A-D). MYCN protein concentrations 
in the QCs were estimated using the standard curve and used to generate acceptance 
criteria for each QC in the assay (Mean concentration ± 30%). In 5 independent repeats 
(each using quadruplicate wells) all assays passed according to the 4-6-30 rule (Smolec et 
al., 2005) demonstrating acceptable assay precision (Supplementary Fig. S3E). 
 
 
3.6 Analysis of MYCN protein in neuroblastoma cells isolated from patient bone 
marrow 
Next, to establish whether MYCN oncoprotein could be measured in neuroblastoma cells 
from patients, bone marrow aspirates from 4 patients (patients 6, 8, 11 and 14, Table 2), 
were subjected to the three-color FACS methodology and the isolated CD45-/GD2+/CD56+ 
neuroblastoma cells were lysed and analyzed for MYCN protein expression using our in-
house immunoassay. We confirmed that MYCN protein was detectable both in the whole 
mononuclear cell population collected from bone marrow, with an increased level after the 
FACS isolation procedure, consistent with the enrichment for MYCN-expressing CD45-
/GD2+/CD56+ neuroblastoma cells (Fig. 5A and B, patient 8). CD45+/GD2-/CD56- white 
blood cells that were isolated concurrently with CD45-/GD2+/CD56+ neuroblastoma cells 
gave signals close to background in the immunoassay, as would be expected in a cell 
population that does not express MYCN. Analysis of bilateral aspirates (from the same 
patient) showed good concordance of MYCN expression, suggesting reproducibility of this 
approach (Fig. 5A and B, patient 8). To further corroborate specificity of the immunoassay 
for measurement of MYCN protein, we confirmed the expression of MYCN in the same bone 
marrow sample by western blotting (Fig 5C). Additionally, analysis of MYCN protein levels in 
three further patients (patients 6, 11 and 14) showed that the highest expression, either pre- 
or post-sorting, was measured in the MYCN amplified patient (Fig. 5D). These data 
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demonstrate that MYCN protein can be quantitatively measured in bone marrow-resident 
neuroblastoma cells both before and after enrichment. 
 
3.7 Measurement of PI3K/AKT/mTOR pathway activity in platelet-rich plasma from 
children 
Since a key driver of MYCN stability in neuroblastoma cells is PI3K/AKT/mTOR signaling, 
we sought to address the need to monitor the activity of this pathway in children with 
neuroblastoma. We chose to determine the feasibility of using the Meso Scale Discovery® 
(MSD®) multiplex electrochemiluminescence platform to measure total and phospho-protein 
signals for AKT, GSK3β and P70S6K, in neuroblastoma cells and also platelet-rich plasma 
(PRP), the latter as a surrogate tissue. These assays have been validated to meet Good 
Clinical Practice requirements and have been used by our laboratory to detect 
PI3K/AKT/mTOR activity in PRP as a surrogate tissue in five adult phase I clinical trials of 
PI3K/AKT/mTOR inhibitors including MK2206 and AZD5363 (Arkenau et al., 2014; Banerji et 
al., 2013; Kumar et al., 2014; Omlin et al., 2012; Yap et al., 2011), but have not been 
evaluated in the pediatric setting until now. 
 
Firstly, we tested whether these assays reliably detect changes in PI3K/AKT/mTOR pathway 
activity in neuroblastoma cells following treatment with the TORC1/TORC2 inhibitor 
AZD8055. We confirmed that phospho- AKT, GSK3β and P70S6K signals decreased 
compared to total levels of each of the biomarkers following 3 h AZD8055 treatment of Kelly 
neuroblastoma cells (Supplementary Fig. S4A and B). We next looked to see whether the 
triplex MSD® assays for AKT pathway activity could be used to measure signals of these 
biomarkers in Kelly neuroblastoma cells, after their isolation from spiked blood by three-color 
sorting. However, compared with the pre-spiked Kelly cells, levels of all three biomarkers 
were considerably reduced following this isolation procedure, resulting in an unreliable 
measurement of AZD8055-mediated inhibition (data not shown). Given that 
PI3K/AKT/mTOR pathway activity can be measured robustly in PRP, commonly used as a 
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surrogate normal tissue for PD assessment (Yap et al., 2014), we next investigated whether 
these assays would be suitable for the detection of these signals in PRP from a pediatric 
population.  Baseline PRP samples from 24 children with solid tumors receiving treatment at 
our unit were collected and divided into three cohorts (1-4, >4-10 and >10-18 years, 
n=8/group) for analysis. Supplementary Table S1a shows demographic characteristics of 
these patients. Baseline signal amplitude and range in PRP was compared to that of 24 
adult patients with solid tumors (Supplementary Table S1b) to establish validity of the assay 
for pediatric patients. Good reproducibility between assays was demonstrated by the 
inclusion of AKT standards and quality controls (Supplementary Figure S5).  
 
Importantly, all pediatric patient PRP samples had detectable total and phosphorylated AKT, 
P70S6K and GSK3β protein levels (Fig. 6A and B). The phospho-AKT signal was 
statistically lower in the pediatric versus adult patient samples (p=0.022), whilst both 
phospho-GSK3β and phospho-P70S6K were significantly higher (p=0.002 and p =0.009 
respectively, Figure 6A). Total AKT and P70S6K levels were not statistically different 
between adult and pediatric patients (p>0.05), whilst total GSK3β was significantly higher in 
the pediatric patients (p=0.002, Figure 6B). Using the ratio of phospho/total levels for each 
biomarker, the level of activated AKT was again statistically lower in the pediatric versus 
adult patient samples (p=0.002), whilst levels of activated GSK3β and P70S6K were slightly 
higher in pediatric samples (p>0.05 and p=0.038, respectively, Fig. 6C). Within the pediatric 
subset of PRP samples, no significant differences were found in the levels of the three 
biomarkers according to age group, disease stage, primary tumor type or MYCN status 
(p>0.05 by  two-tailed t test).  
 
Taken together, these preliminary data indicate that these assays could be used to 
accurately measure PI3K/AKT/mTOR pathway activity in pediatric PRP as a surrogate 
tissue, and additionally detect pathway inhibition in cells treated with a drug we propose to 
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use in clinical evaluation. Therefore, we propose that the MSD® assays are fit-for-purpose to 




Development of pediatric early phase clinical trials with biomarkers utilizing novel anticancer 
drugs has traditionally lagged behind that of adult cancers. In part this relates to lack of 
biopsy tissue in children, and to a deficiency in PD assays robust enough to support clinical 
trials. It is now crucial to develop and implement appropriate PD biomarkers in early phase 
clinical trials for childhood cancers to ensure that these trials are as informative as possible. 
Analysis of PD biomarkers has two key objectives: i) to determine whether novel targeted 
drugs inhibit the expected target(s) in patient tissue (tumor or surrogate) i.e. proof of 
mechanism, and ii) to ascertain whether modulation of the drug target results in the expected 
biological downstream effect(s) i.e. proof of concept. PD biomarker assays are therefore 
valuable components of the pharmacological audit trail to evaluate new molecular targeted 
drugs (Workman, 2003). 
 
We report for the first time the development of a panel of PD biomarker assays and 
methodology to isolate metastatic neuroblastoma cells for PD biomarker analysis, these 
assays are ready to be implemented in early phase clinical trials of agents targeting PI3K, 
AKT or the mTOR complex and provide the opportunity to demonstrate both proof of 
mechanism and proof of concept for these agents in neuroblastoma. The rationale for using 
these classes of inhibitors in neuroblastoma and other MYCN-driven tumors is that the 
pathway is either dysregulated or mutated in several pediatric malignancies, and that 
blockade of PI3K/AKT/mTOR will lead to degradation of MYCN protein.  
 
One of the biggest challenges to incorporating PD biomarkers in early pediatric clinical trials 
remains obtaining suitable tissues, either tumor material or appropriate surrogate tissues 
(Ang et al., 2012; Gainor et al., 2014). In neuroblastoma, tumor mass at relapse is generally 
small, localizes to bone or is otherwise inaccessible (e.g. retroperitoneal or mediastinal) and 
therefore repeated tumor biopsies are challenging. Circulating cell free tumor DNA 
represents one option for measuring cancer-associated genetic alterations during treatment. 
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Bone marrow samples are also routinely collected, commonly with detectable tumor 
infiltration, although the number of cells is variable. Several groups have used 
immunomagnetic separation methods to isolate neuroblastoma cells from bone marrow 
samples for genomic or cell surface expression studies (Abbasi et al., 2015; Morandi et al., 
2012; Scaruffi et al., 2012; Vandewoestyne et al., 2012). We found this technique to be 
unsuitable for our purposes as it involved several steps that led to significant cell loss and 
greater variability and resulted in poorer final purity of neuroblastoma cells than FACS.  
 
Flow cytometry is commonly used for diagnosis and research studies in neuroblastoma but 
cell sorting has not been applied for pharmacodynamic studies before. Using a three-color 
FACS-based method we obtained cell suspensions with a high purity for neuroblastoma, 
with acceptable cell loss and preserved MYCN protein signals when processing was initiated 
up to 4 hours after sample collection. FACS sorting provides an opportunity for biomarker 
monitoring in tumor cells themselves from routine bone marrow aspirates without the need 
for additional biopsies. This methodology has particular importance when tumor cell-specific 
biomarkers such as MYCN protein are to be measured as there is no alternative option of 
using surrogate tissues. Therefore, we propose that isolating neuroblastoma cells from bone 
marrow as a substrate for protein-based PD biomarker assays could be combined with the 
use of more readily available surrogate tissues (such as PRP) in early clinical trials to 
provide a fully comprehensive overview of drug-mediated biomarker responses.   
 
Previous pediatric phase I trials of mTOR inhibitors have measured phosphorylation of AKT 
and S6 kinase in PBMCs using western blotting and/or immunohistochemistry. In the phase I 
trial of Temsirolimus there was no evidence of a PK/PD relationship as assessed by 
phosphorylation of AKT, p70S6K or 4EBP1 by western blotting (Spunt et al., 2011). 
However, in the phase I study of Everolimus, decreases in AKT phosphorylation were 
detected by western blotting following treatment (Fouladi et al., 2007) and in a phase I trial of 
Ridaforolimus, inhibition of p4EBP1 was demonstrated for the majority of patients, again by 
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western blotting (Gore et al., 2013).  Although these studies have begun to monitor PD 
biomarkers in pediatric patients, the traditional histology and immunoblotting methodologies, 
which have not been specifically optimized for this purpose, have a number of deficiencies 
e.g. limited and/or unspecified sensitivity, qualitative or semi-quantitative, and no integrated 
measure of assay performance and reproducibility. 
 
In the pediatric setting where phase I studies may be conducted in 10 or more sites, 
standard operating procedures for sample collection and processing  are vital to ensure that 
results from multiple sites are comparable (Kinders et al., 2014). Assays require thorough 
optimization and evaluation to ensure that they are fit-for-purpose and the inclusion of 
appropriate controls is paramount. We have performed substantial analytic method 
validation and included standard and quality controls to ensure reliability and reproducibility 
of PD biomarker assays for PI3K/AKT/mTOR pathway activity and MYCN oncoprotein.   
 
Here we show that the AKT triplex MSD® assays for phospho and total AKT, GSK3 and 
P70S6K can be used in the pediatric oncology population with several advantages over 
histology and western blotting techniques. Specifically, these assays provide a quantitative 
non-invasive measure of three pathway-specific markers simultaneously, thus requiring 
smaller samples and giving a more reliable measurement of pathway activation. Using these 
assays, some of the baseline values in pediatric patients were significantly different from 
those in adults. Further comparing the levels of phospho and total AKT, GSK3β and 
P70S6K, we found no correlation with age, tumor type, disease stage or MYCN status within 
the pediatric samples. It is difficult to speculate on the reason for the variation in this 
surrogate tissue between children and adults and indeed whether our results represent 
genuine differences due to the relatively small sample populations. Most importantly we 
have determined that the assays are fit-for-purpose in the pediatric setting with signals within 
the detectable range and provide the opportunity to demonstrate proof of mechanism in 




To date, western blotting has remained the gold standard for MYCN protein quantification 
(Cohn et al., 2000). Here, we present a new immunoassay that will allow the robust 
measurement of MYCN protein levels in patients receiving MYCN-targeted therapies using 
smaller samples than western blotting and with the inclusion of appropriate assay controls 
for performance monitoring. MYCN protein can be measured in bone marrow aspirates from 
neuroblastoma patients with bone marrow involvement, however due to the high variability in 
the percentage of tumor cells present, we recommend that neuroblastoma cell enrichment 
by FACS is performed to allow better comparison of MYCN levels in paired pre-treatment 
and post-treatment samples in a clinical trial. Additionally, we show that MYCN signals 
remain stable in lysates, once frozen, for at least 4 weeks, thus providing the opportunity to 
transport samples to a central laboratory to run the MYCN immunoassay. Measuring 
changes in MYCN levels during the clinical trials will test the hypothesis developed pre-
clinically that PI3K inhibitors exert their antitumor activity in-part via destabilization of MYCN 
protein and therefore has the potential to deliver proof of concept for these agents (Chesler 
et al., 2006).  
 
In conclusion, we have provided pre-clinical and clinical validation of assays to measure 
PI3K/AKT/mTOR pathway signaling and MYCN protein expression as well as a method to 
isolate neuroblastoma cells for protein biomarker analysis. These PD assays have the 
potential to deliver both proof of mechanism and proof of concept for new drugs that target 
the PI3K/AKT/mTOR pathway and are now ready to be implemented as a research endpoint 
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Figure 1.  Isolation of neuroblastoma cells by fluorescence activated cell sorting 
(A) Flow cytometry dotplots of PBMCs and/or Kelly cells labelled with GD2-PE, CD56-FITC 
and CD45-APC H7 antibodies pre- and post- FACS sorting. High and low spiked samples 
were 1.5 x106 and 3 x 105 Kelly cells into 6ml whole blood, respectively. Thick black boxes 
indicate quadrants for isolated GD2+/CD56+/CD45- neuroblastoma cells. (B) The 
percentage of Kelly cells (GD2+/CD56+/CD45-) pre- and post- FACS cell sorting. The mean 
fold enrichment of Kelly cells from the spiked samples is indicated in brackets above the post 
bars. Mean±SD from 3 independent experiments. **p value<0.01, ***p value<0.001 by 
unpaired t test.  (C) Recovery rates of Kelly cells by FACS cell sorting  = (Number of Kelly 
cells collected from cell sorter/Total Kelly cells added to sample before sorting)x100, 
Mean±SD from 3 independent experiments. PBMC: peripheral blood mononuclear cells 
 
Figure 2.  Neuroblastoma cell enrichment from patient bone marrow aspirates 
Bone marrow aspirates from neuroblastoma patients were sorted by FACS to isolate 
GD2+/CD56+/CD45- cells. (A) Example flow cytometry dotplots from a single bone marrow 
aspirate pre- and post-sorting. Thick black boxes indicate quadrants for GD2+/CD56+/CD45- 
neuroblastoma cells. (B) The percentage of neuroblastoma cells in 11 bone marrow samples 
pre- and post-sorting is plotted for patients in which GD2+/CD56+/CD45- cells were 
detected.  Five post-sorted samples had ≤10,000 cells and purity was not determined (See 
Table 2). 
 
Figure 3.  An immunoassay to measure MYCN protein in neuroblastoma cells 
(A) Titration of recombinant MYCN protein shows linearity in MYCN immunoassay.  
Mean±SD from 4 independent repeats. (B) MYCN protein levels in 6 neuroblastoma cell 
lines (3 with amplified MYCN) by immunoassay using 25µg or 10µg of total protein.  
Mean±SD of 3 independent repeats. (C) MYCN protein levels by western blot using cell 
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lysates from (B). (D) Western blot for AZD8055 treated Kelly cells (3h) showing a dose-
dependent depletion of MYCN protein. (E) Quantitation of dose-dependent MYCN protein 
depletion levels by AZD8055 in Kelly cells by immunoassay. Mean±SD of 3 independent 
repeats. **p value<0.01, ***p value<0.001 compared with no treatment control by one-way 
ANOVA followed by Dunnett’s multiple comparison test. 
 
Figure 4.  Measurement of MYCN protein in isolated neuroblastoma cells 
(A) MYCN protein levels in pre- and post-sorted Kelly spiked PBMCs or PBMCs alone 
relative to Kelly cells alone in samples processed after 0, 1, 4 or 24 hours. Mean±SD from 3 
independent experiments. **p value<0.01 compared with Kelly only by one-way ANOVA 
followed by Dunnett’s multiple comparison test. (B) MCYN protein levels in Kelly cells 
isolated from spiked healthy volunteer blood and lysed and either frozen immediately at -
80ºC or stored overnight on dry ice then frozen at -80ºC. Samples were analyzed by MYCN 
immunoassay after 1 day, 1 week or 4 weeks of storage. (C) Schematic of the suggested set 
up for bone marrow processing, transport, storage and biomarker measurement for MYCN 
protein analysis in a multi-site clinical trial context. (D) MYCN protein levels measured in 
immunoassay pre- and post- enrichment of Kelly neuroblastoma cells by FACS sorting using 
5μg total protein per sample and compared with PBMC only samples. High and low spiked 
samples were 1.5 x106 and 3 x 105 Kelly cells into 6ml whole blood, respectively. Mean±SD 
from 3 independent experiments. *p value<0.05, ns=not significant by unpaired t test. (E) 
MYCN protein levels quantified by immunoassay for pre-sorted PBMCs with spiked Kelly 
cells (grey bars) or post-sorted spiked Kelly cells (black bars). Samples were untreated or 
treated for 3h with 5µM or 40 µM AZD8055 Mean±SD from 3 independent experiments. *p 
value<0.05, **p value<0.01, ns=not significant compared with no treatment control by one-
way ANOVA followed by Dunnett’s multiple comparison test. 
 
Figure 5.  Measurement of MYCN protein in patient bone marrow samples 
31 
 
Neuroblastoma cells were isolated from left (A) and right (B) bone marrow aspirates and 
MYCN protein expression analyzed by immunoassay. Equal amounts of total protein/well 
were used for each set of samples (20µg for 8R and 6µg for 8L) and lysates were run in 
duplicate. Pre-sorted bone marrow (grey bars) and post-sorted neuroblastoma cells (black 
bars) are compared with sorted white blood cells (white bars). (C) MYCN expression was 
confirmed in bone marrow from patient 8 by western blotting, with Kelly cell lysate used as a 
positive control for MYCN protein. (D) Neuroblastoma cells were isolated from bone marrow 
aspirates from three additional patients and MYCN protein expression analyzed by 
immunoassay. Equal amounts of total protein/well were used for each set of samples (as 
indicated) and lysates were run in duplicate. Pre-sorted bone marrow (grey bars) and post-
sorted neuroblastoma cells (black bars) are compared with sorted white blood cells (white 
bars). 
 
Figure 6.  PI3K/AKT/mTOR pathway activity in platelet-rich plasma 
(A) Phospho AKT (pS473), GSK3β (pS9), P70S6K (pT421/pS424) and (B) total AKT, 
GSK3β and P70S6K signals for 24 adult and 24 pediatric patient PRP samples detected 
using the MSD® triplex assay plates for phospho and total signals. ECL: 
Electrochemiluminescence. (C) Ratios of phospho over total protein levels for AKT, GSK3β 
and P70S6K for each patient shows the proportion of kinases that are active. Adult results 
are shown in grey and pediatric results in black. Mean values for each data set are shown 
above and represented by black bars. *p value<0.05, **p value<0.01 by unpaired two-tailed t 
test. 
 
Table 1.  Comparison of neuroblastoma isolation methods 
Kelly cells were spiked into whole blood followed by Lymphoprep™ isolation of the peripheral 
blood mononuclear cell (PBMC) fraction. Results show flow cytometry analysis of Kelly cell 
populations pre- and post- neuroblastoma cell isolation techniques using CD56 positive 
selection (CD56 MACS microbeads), CD45 negative selection (CD45 MACS microbeads) or 
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3-color (APC-H7-CD45, PE-GD2 and FITC-CD56) fluorescence activated cell sorting 
(FACS).  Mean±SD, n≥3 
 
Table 2.  Summary of neuroblastoma cell isolation from patient bone marrow 
Patient bone marrow aspirates with detectable neuroblastoma infiltration were sorted by 
FACS. The level of neuroblastoma cells (CD45-/GD2+/CD56+) detected pre-sorting, fold 
enrichment following sorting and the total number of neuroblastoma cells collected is shown 
for each sample. Independent analysis of bone marrow infiltration was performed from bone 
marrow smears/trephine biopsies and results classed as ‘No detection’, ‘Tumor cells 
detected’ or ‘Heavy infiltration’. The extent of bone marrow infiltration detected by flow 
cytometry is catergorized as follows: Very low <0.1%, Low >0.1-1%, Medium >1-10% and 
High >10%. ND=Not determined (due to very low cell numbers).  Patients 1, 2, 3, 4, 7, 9 and 
12 did not show any detectable bone marrow infiltration by FACS or independent analysis 
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Isolation technique Selection marker(s) % PRE % POST Fold enrichment
Immunomagnetic beads CD56 positive 16.0 ±3.3 26.8 ±5.0 1.7 ±0.3
Immunomagnetic beads CD45 negative 14.6 ±3.8 58.2 ±28.2 3.9 ±1.3








Detection of bone marrow resident
neuroblastoma cells
Post-sorting









Left Very low No detection ND 1000
Right Very low No detection ND 1100
6 Non-amplified
Left Very low ND ND 1500
Right Medium Heavy infiltration 11.5 470000
8 Non-amplified
Left Medium Heavy infiltration 12.0 785000
Right Medium Heavy infiltration 10.9 605000
10 Amplified Unknown Low Tumor cells detected ND 10000
11 Unknown Right High Heavy infiltration 3.7 2190000
13 Amplified
Left Low Tumor cells detected 337.5 26000
Right Low Tumor cells detected ND 6500
14 Amplified Left Medium Heavy infiltration 14.8 266000
Table 2
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